Abstract:SESSION TITLE: Asthma IV SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Eosinophilic airway inflammation can predict the exacerbation of asthma, and we can improve the management of asthma by monitoring the eosinophilic airway inflammation. Although induced sputum and sputum eosinophil count is the gold standard test for diagnosing eosinophilic asthma, a more accessible and receptive method is needed for clinical practice. Type 2 innate lymphoid cells (ILC2) have recently been proposed to play a crucial role in eosinophilic inflammation and have been identified in peripheral blood from patients with asthma. We sought to identify simple and feasible biomarkers which can predict eosinophilic airway inflammation in asthmatic patients. METHODS: Sputum was induced for the assessment of eosinophils in 150 asthmatic patients. In parallel, the proportion of ILC2s of peripheral blood lymphocytes (%ILC2), blood eosinophil counts, total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO) and lung function tests were measured. RESULTS: 126 patients finished sputum induction and produced adequate sputum. The ILC2 level was significantly increased in eosinophilic asthmatic patients compared with non-eosinophilic asthmatic patients (0.117±0.090versus0.035±0.021, p<0.001). A multiple regression model, including age, sex, BMI, blood eosinophil counts, FeNO, IgE and %ILC2, showed that %ILC2, blood eosinophil counts and FeNO were correlative factors of sputum eosinophil counts (p<0.001, p=0.037, p<0.001, respectively) and %ILC2 was the most significant subset of airway eosinophilic inflammation (Estimate=11.385). A receiver operating characteristic (ROC) analysis showed a sensitivity of 67.7% and a specificity of 95.3% for %ILC2 of 0.076 to distinguish eosinophilic asthmatic patients from non-eosinophilic asthmatic patients. CONCLUSIONS: ILC2 is a surrogate marker of airway eosinophilic inflammation in patients with mild to moderate asthma and has great potential advantages for selecting the asthmatic patients most likely to benefit from therapeutics targeting Th2 inflammation. CLINICAL IMPLICATIONS: Our study demonstrates that blood ILC2 can reflect airway eosinophilic inflammation in mild to moderate asthmatic patients, and this provides a new insight for the biomarker of eosinophilic asthma. The level of ILC2 might help identify and select those patients most likely to respond to these biological therapeutics. DISCLOSURE: The following authors have nothing to disclose: Liang Dong No Product/Research Disclosure Information

Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthma

JAK-1 Rs2780895 C-Related Genotype and Allele but Not JAK-1 Rs10789166, Rs4916008, Rs2780885, Rs17127114, and Rs3806277 Are Associated with Higher Susceptibility to Asthma

Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma.

Genome-wide Association Analysis in Asthma Subjects Identifies SPATS2L As a Novel Bronchodilator Response Gene.

Type‐2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide

Two Single Nucleotide Polymorphisms in TSLP Gene Are Associated with Asthma Susceptibility in Chinese Han Population

Phenotypic and functional translation of IL33 genetics in asthma

A common polymorphism in the Intelectin-1 gene influences mucus plugging in severe asthma

Convergent Evidence Supports TH2LCRR as a Novel Asthma Susceptibility Gene

Lung Expression Quantitative Trait Loci Data Set Identifies Important Functional Polymorphisms in the Asthma-Associated IL1RL1 Region.

Type 2 inflammation in asthma and other airway diseases

Type 2 Innate Lymphoid Cells: A Novel Biomarker of Eosinophilic Airway Inflammation in Patients with Mild to Moderate Asthma

Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations

Genetic variants of IL-13 signalling and human asthma and atopy

Late Breaking Abstract - Patient stratification of two asthma populations reveal distinct genetic and mechanistic differences between T2-high and T2-low asthma

Associations Between Th17-related Inflammatory Cytokines and Asthma in Adults: A Case-Control Study.

Treatment options in type-2 low asthma

Prioritization of candidate causal genes in GWAS signals of asthma in UK Biobank

Convergent Evidence SupportsTH2LCRRas a Novel Asthma Susceptibility Gene

Transcriptomic analysis of asthma and allergic rhinitis reveals CST1 as a biomarker of unified airways

Shared genetic architecture of blood eosinophil counts and asthma in UK Biobank